I’ve had a few friends treated with immunotherapy in the past 5 or 10 years. So i think it’s mainstream, at least for some cancers.
That was true around when I had cancer treatment. I just missed the shift. Now it’s pretty available.
Mom mother gets immunotherapy for her cancer every other week.
My sister is getting immunotherapy for malignant melanoma as we speak.
Why is private founding so little? Why is most of the money going to cancer research coming from the government?
Also why does pharmaceutical companies do so little when it comes to new treatments?
In the U.S., the federal government provides core sources of support for basic biomedical research and development. In general terms, 64 percent of all applied biomedical R&D funding comes from within the industry, while just 22 percent comes from the federal government.
The NIH is in danger of losing its edge in creating biomedical innovations.
However, we have too often not been able to support many opportunities that could help us better understand, prevent, detect, and treat cancer. That’s because reduced buying power has prohibited NCI from funding a substantial proportion of the meritorious applications we receive each year. As shown in the FY25 budget proposal, NCI’s buying power to support cancer research, including clinical trials and critical infrastructure, is 13% less in 2023 than it was in 2003. This means, in today’s dollars, we can fund $1.1 billion less cancer research now than we could 20 years ago.
This post follows multiple posts discussing new treatments from pharmaceuticals from the last decade or so. Are you reading any of the responses at all?
I have also been reading here and there the use of nano particles use to fight cancer. I’m not sure what nano particles are or why they use them.
As our understanding of malignancies and their connection to the immune system improves, there has been a growing interest in priming the immune system to fight malignancies more effectively and comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which has been shown to potentiate immune responses as vaccines and/or adjuvants.